ATAurélien Trompette

Aurélien Trompette

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aurélien Trompette has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation.

    by Ana Alcaraz-Serna, Noémie Chillier, Aurélien Trompette, Laura Ermellino, Raphaël Porret, Erica Lana, Rebecca Cecchin, Apiha Shanmuganathan, Seher Guney, Oscar Alfageme-Abello, et al.

    Asthma is a deadly chronic respiratory disease affecting over 300 million people. While allergen immunotherapy remains the only disease-modifying treatment, it is poorly applicable for patients with severe asthma. Here, we explored the therapeutic potential of regulatory T cells (Tregs) armed with chimeric allergen receptors-named CAlleR-redirected against the major allergen of birch pollen Bet v1. Four novel anti-Bet v1 antibodies were identified and used to engineer and functionally validate CAlleR. CAlleR Tregs showed specific in vitro activation and suppression and significantly reduced the airway hyperresponsiveness in birch pollen-sensitized mice. Mechanistically, CAlleR Tregs migrated to the lungs and mediastinal lymph nodes, interacted with CD11c+ dendritic cells, and were activated in a FcγR-dependent manner by cross-presenting Bet v1 stabilized with noncompetitive anti-Bet v1 antibodies. These findings unveil a novel mechanism for targeting soluble antigens and highlight the potential of CAlleR Tregs to prevent and treat severe allergies.


  • Open Access

    Respiratory and Gut Microbiota Correlate with Lung Function Recovery after Severe COVID-19

    by Sabine V Stadler, Luca C Stickley, Eric Bernasconi, Seher Guney, Aurélien Trompette, Lise Piquilloud, Manuela Funke-Chambour, Christophe von Garnier, Niki D Ubags

    Rationale: Severe SARS-CoV-2 infection induces disrupted oropharyngeal and gut microbiota during acute disease which may persist and contribute to the development of post-acute pulmonary sequelae. To date, it is unclear whether dysbiosis following severe disease is linked to long-term pulmonary function impairment. Objectives: To determine associations between oropharyngeal and gut microbiota composition with lung function after severe COVID-19. Methods: 16S and internal transcribed spacer (ITS) rRNA amplicon sequencing were performed on oropharyngeal (16S and ITS) and rectal (16S) swabs at 3-, 6- and 12-months post-hospitalisation from 83 subjects previously admitted to the ICU with severe COVID-19 (Swiss COVIDlung study, NCT04581135 ). Subjects underwent 1-3 follow-up visits during which lung function testing was performed to investigate associations with microbiota composition. Measurements and Main Results: The oropharyngeal microbiota of subjects having suffered from COVID-19-related-severe acute non-cardiogenic hypoxemic respiratory failure with bilateral lung infiltrates (AHRF-BLI) was characterized by decreased α-diversity and the presence of differentially abundant taxa. Subjects who recovered in lung function (TLC, FVC, FEV 1 and DLCO >Lower Limit of Normal) had a distinct oropharyngeal and gut microbiota composition compared to those whose lung function never recovered. Fungal analysis of oropharyngeal samples revealed the presence of three distinct clusters which were characterized by distinct lung-function associated bacterial-fungal co-occurrence. Conclusions: This study provide first insights into the role of the airway and gut microbiota in the development of long-term pulmonary sequelae after severe SARS-CoV-2 infection, shedding the light on the potential of the microbiota for preventive and therapeutic strategies in severe COVID-19.


  • Open Access

    Prevalence of oxalotrophy in the human microbiome

    by Thomas Junier, Fabio Palmieri, Niki D. Ubags, Aurélien Trompette, Angela Koutsokera, Pilar Junier, Marco Pagni, Samuel Neuenschwander

    Incomplete degradation of oxalate, a compound commonly found in the diet, can lead to disease in humans, particularly affecting the kidneys. The concentration of oxalate in the body depends on several factors, one of which is intestinal absorption—an aspect influenced by oxalotrophy among enteric bacteria. Despite its potential significance, oxalotrophy in the human microbiome remains poorly understood. In this study, we conducted a systematic search for the co-occurrence of three key oxalotrophy genes—frc, oxc, and oxlT. We developed and validated specific conservation models for each gene and applied them to genomes and metagenomes associated with the human digestive tract, oral cavity, and lungs. Our analysis revealed that oxalotrophy, defined as the capacity to use oxalate as an energy source, is a rare metabolic trait predominantly confined to the gut. We also found evidence that this capacity can be acquired via horizontal gene transfer. While oxalotrophy is relatively uncommon, the broader capacity for oxalate degradation is more widespread. Notably, the genes frc and oxc are frequently found in close proximity within genomes, suggesting a selective advantage for organisms possessing this capability. Incomplete degradation of oxalate, a compound commonly found in the diet, can cause disease in humans, particularly affecting the kidney. Its concentration in the body depends on several factors, one of which is intestinal absorption, which is itself affected by oxalotrophy among enteric bacteria. Oxalotrophy in the human microbiome is poorly known. In this study, we perform a systematic search for the simultaneous presence of the three oxalotrophy genes, namely frc, oxc and oxlT. Thanks to the construction and validation of specific conservation models for all three genes, we were able to search for oxalotrophy in genomes and metagenomes associated with the human digestive tract, oral cavity, and lungs. We report that oxalotrophy—the capacity to use oxalate as an energy source—is a rare metabolic trait, mostly confined to the gut, and also find evidence that it can be acquired by horizontal gene transfer. By contrast, the capacity for oxalate degradation is more widespread, and two genes responsible for it (frc and oxc) are almost always close together in the genome, suggesting selection pressure.


  • Open Access

    Fighting Aspergillus infection using biocontrol bacteria: A proof-of-concept of environmental interference in a translational setting

    by Fabio Palmieri, Aurélien Trompette, Apiha Shanmuganathan, Aureline Bouchard, Julie Pernot, Thomas Junier, Julia M. Kelliher, Patrick S.G. Chain, Jennifer Foster Harris, Armelle Vallat, et al.

    Aspergillus fungi are opportunistic pathogens that affect millions of people worldwide. Aspergilli produce organic acids to optimize the environmental pH and match the needs of their enzymatic machinery. In this study, we tested the hypothesis that this also occurs during infection. By producing oxalic acid (OA), Aspergillus would manipulate pH during lung infection and thus, interfering with this process could control the pathogen. To test this hypothesis, we assessed in silico the potential for OA production in a wide range of Aspergilli. A genetic marker for AO production was detected in most of the species including prevalent human pathogens. We tested OA production in vitro in four strains of A. niger and A. fumigatus , but only one of the A. niger strains produced OA consistently. For this fungal strain, oxalotrophic bacteria were able to control fungal growth via OA consumption. To translate this observation into a pre-clinical system, increasingly complex experiments were performed. In 3D-cell cultures, A. niger also secreted OA and modified pH and free Ca 2+ . Co-inoculation of the oxalotrophic bacterium inhibited the development of the fungus. However, biocontrol could not be replicated in Galleria mellonella , which is often used as an infection model. In contrast, the bacterium improved disease score and the absence of oxalate crystals in the lungs in the mouse model. This biocontrol interaction between oxalotrophic bacteria and A. niger represents a paradigm shift in the fight against opportunistic fungal pathogens, where the goal is to render the host environment less permissive to pathogen development One Sentence Summary: Demonstration of biocontrol as a therapeutic concept to combat Aspergillus niger with oxalotrophic bacteria in an animal infection model


  • Open Access

    Prevalence of Oxalotrophy in the Human Microbiome

    by Thomas Junier, Fabio Palmieri, Niki D. Ubags, Aurélien Trompette, Angela Koutsokera, Pilar Junier, Marco Pagni, Samuel Neuenschwander

    Incomplete degradation of oxalate, a compound commonly found in the diet, can cause disease in humans, particularly of the kidney. Its concentration in the body depends on several factors, one of which is intestinal absorption, which is itself affected by oxalotrophy among enteric bacteria. Oxalotrophy in the human microbiome is poorly known. In this study, we perform a systematic search for the simultaneous presence of the three oxalotrophy genes, namely frc , oxc and oxlT. Thanks to the construction and validation of specific conservation models for all three genes, we were able to search for oxalotrophy in genomes and metagenomes associated with the human digestive tract, oral cavity, and lungs. We report that oxalotrophy - the capacity to use oxalate as a source of energy - is a rare metabolic trait, mostly confined to the gut, and also find evidence that it can be acquired by horizontal gene transfer. By contrast, the capacity for oxalate degradation is more widespread, and two genes responsible for it ( frc and oxc ) are almost always close together in the genome, suggesting selection pressure.

  • Open Access

    One-Step Soft Agar Enrichment and Isolation of Human Lung Bacteria Inhibiting the Germination of Aspergillus fumigatus Conidia

    by Fabio Palmieri, Jérémy Diserens, Manon Gresse, Margo Magnin, Julina Helle, Benoît Salamin, Lorenzo Bisanti, Eric Bernasconi, Julie Pernot, Apiha Shanmuganathan, et al.

    Fungi of the genus Aspergillus are widespread in the environment, where they produce large quantities of airborne conidia. Inhalation of Aspergillus spp. conidia in immunocompromised individuals can cause a wide spectrum of diseases, ranging from hypersensitivity responses to lethal invasive infections. Upon deposition in the lung epithelial surface, conidia encounter and interact with complex microbial communities that constitute the lung microbiota. The lung microbiota has been suggested to influence the establishment and growth of Aspergillus spp. in the human airways. However, the mechanisms underlying this interaction have not yet been sufficiently investigated. In this study, we aimed to enrich and isolate bacterial strains capable of inhibiting the germination and growth of A. fumigatus conidia from bronchoalveolar lavage fluid (BALF) samples of lung transplant recipients using a novel enrichment method. This method is based on a soft agar overlay plate assay in which bacteria are directly in contact with conidia, allowing inhibition to be readily observed during enrichment. We isolated a total of five clonal bacterial strains with identical genotypic fingerprints, as shown by random amplified polymorphic DNA PCR (RAPD–PCR). All strains were identified as Pseudomonas aeruginosa (strains b1–b5). The strains were able to inhibit the germination and growth of Aspergillus fumigatus in a soft agar confrontation assay, as well as in a germination multiplate assay. Moreover, when compared with ten P. aeruginosa strains isolated from expectoration through standard methods, no significant differences in inhibitory potential were observed. Additionally, we showed inhibition of A. fumigatus growth on Calu-3 cell culture monolayers. However, the isolated P. aeruginosa strains were shown to cause significant damage to the cell monolayers. Overall, although P. aeruginosa is a known opportunistic lung pathogen and antagonist of A. fumigatus, we validated this novel one-step enrichment approach for the isolation of bacterial strains antagonistic to A. fumigatus from BALF samples as a proof-of-concept. This opens up a new venue for the targeted enrichment of antagonistic bacterial strains against specific fungal pathogens.


  • Fighting aspergillosis using biocontrol bacteria

    by Aurélien Trompette, Apiha Shanmuganathan, Julie Pernot, Fabio Palmieri, Eric Bernasconi, Christophe Von Garnier, Janick Stucki, Nina Hobi, Pilar Junier, Angela Koutsokera, et al.

    Development of alternative treatments for fungal infections is imperative with the rapid increase in antifungal resistance worldwide. Aspergillus spp. infection can modify the lung microenvironment and promote growth via oxalic acid release. In vitro, Cupriavidus oxalaticus was shown to degrade oxalic acid, thereby decreasing Aspergillus spp. growth. We aimed to optimize experimental models to demonstrate the potential of this biocontrol mechanism for clinical interventions. BalbC/J mice were treated with cyclophosphamide and cortisone acetate followed by lung infection with A. fumigatus CEA10, colonization with C. oxalaticus, or a combination of both. Immune cell composition and hyphal development were evaluated in BALF and lung tissue after 72h. To investigate this process in a clinically relevant context, the same approach was applied on human-derived immortalized alveolar epithelial cells (AXiAEC) cultured on AXlung-on-chip. Transepithelial electrical resistance, cell morphology, and oxalic acid levels were assessed. We optimized an A. fumigatus infection dose leading to hyphal formation in the lungs but with minimal distress for the animals. Colonization with C. oxalaticus led to immune priming with negligible airway inflammation. C.oxalaticus exposure altered AXiAEC morphology and enhanced barrier integrity in vitro. Moreover, initial results indicate that C. oxalaticus colonization can control A. fumigatus infection development both in vivo and in vitro. We successfully optimized clinically relevant experimental models to test the potential of biocontrol by environmental interference in the context of pulmonary aspergillosis. This is the first time that biocontrol bacteria are used to contain respiratory fungal infection.

  • Open Access

    One-Step Soft Agar Enrichment and Isolation of Human Lung Bacteria Inhibiting the Germination of Aspergillus fumigatus conidia

    by Fabio Palmieri, Margo Magnin, Jérémy Diserens, Manon Gresse, Eric Bernasconi, Julie Pernot, Apiha Shanmuganathan, Aurélien Trompette, Christophe Von Garnier, Thomas Junier, et al.

    Fungi of the genus Aspergillus are widespread in the environment where they produce large quantities of airborne conidia. Inhalation of Aspergillus spp. conidia in immunocompromised individuals can cause a wide spectrum of diseases, ranging from hypersensitivity responses to lethal invasive infections. Upon deposition in the lung epithelial surface, conidia encounter and interact with complex microbial communities that constitute the lung microbiota. The lung microbiota has been suggested to influence the establishment and growth of Aspergillus spp. in the human airways. However, the mechanisms underlying this interaction have not yet been sufficiently investigated. In this study, we aimed to evaluate the presence of commensal bacteria antagonistic to Aspergillus in the lung. To this end, we enriched and isolated bacterial strains able to inhibit the germination of conidia from bronchoalveolar lavage fluid (BALF) samples of lung transplant recipients. We used a novel enrichment method based on a soft agar overlay plate assay in which bacteria are directly in contact with conidia and for which inhibition can be readily observed during enrichment. We isolated a total of five bacterial strains, identified as Pseudomonas aeruginosa, and able to inhibit the germination and growth of Aspergillus fumigatus in a soft agar confrontation assay, as well as in a high-throughput multiplate assay. Moreover, we also showed a strong inhibition of A. fumigatus growth on Calu-3 cell culture monolayers. However, the isolated P. aeruginosa strains were shown to cause significant damage to the cell monolayers. Overall, we validated this novel one-step enrichment approach for the isolation of bacterial strains antagonistic to A. fumigatus from BALF samples. This opens up a new venue for targeted enrichment of antagonistic bacterial strains against specific fungal pathogens.

  • Open Access

    Skin barrier immunology from early life to adulthood

    by Aurélien Trompette, Niki D. Ubags


  • Top Cited Papers
    Open Access

    Gut-derived short-chain fatty acids modulate skin barrier integrity by promoting keratinocyte metabolism and differentiation

    by Aurélien Trompette, Julie Pernot, Olaf Perdijk, Rayed Ali A. Alqahtani, Jaime Santo Domingo, Dolores Camacho-Muñoz, Nicholas C. Wong, Alexandra C. Kendall, Andreas Wiederkehr, Laurent P. Nicod, et al.